COMP <GO>
PFE vs BMY // EV/EBITDA & P/E VALUATION
Pfizer Inc. (NYSE) VS. Bristol-Myers Squibb Company (NYSE) • 15-METRIC TALLY: PFE 4
— BMY 9
▲ EV/EBITDA & P/E VALUATION LEADER: BMY
LAST: $30.52 (+1.90%) • MKT CAP: $170.71B
valuation
19.7x
LAST: $62.48 (+1.78%) • MKT CAP: $125.40B
valuation
16.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PFE VS. BMY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PFE | BMY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.30% | 71.10% | +3.20 | PFE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.10% | 13.30% | -8.20 | BMY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.7x | 16.3x | +3.40 | BMY | /valuation <GO> |
| Free Cash Flow Yield | 5.32% | 10.24% | -4.92 | BMY | /fcf-yield <GO> |
| Operating Margin | 15.10% | 17.90% | -2.80 | BMY | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 14.60% | -2.20 | BMY | /net-margins <GO> |
| Revenue Growth (YoY) | -1.60% | -0.20% | -1.40 | BMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 4.02% | -4.02 | BMY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.10 | 2.24 | -0.14 | BMY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 50.4 | +8.10 | PFE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.98 | +0.07 | PFE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.5x | 16.6x | +3.90 | BMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $170.71B | $125.40B | $45.30B | PFE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PFE REV | BMY REV | PFE GROSS % | BMY GROSS % | PFE FCF | BMY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.58B | $48.19B | 74.3% | 71.1% | $9.07B | $12.85B |
| FY 2024 | $63.63B | $48.30B | 71.9% | 71.1% | $9.84B | $13.94B |
| FY 2023 | $50.91B | $45.01B | — | — | $6.41B | $11.83B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PFE // BETA 1.05
BMY // BETA 0.98